Targeted toxins

Arthur E. Frankel, Robert J. Kreitman, Edward A. Sausville

Research output: Contribution to journalShort survey

161 Scopus citations


Targeted toxins, consisting of tumor-selective ligands coupled to polypeptide toxins, represent a new class of cancer therapeutics that kills malignant cells by inactivating cytosolic protein synthesis and inducing apoptosis. A number of these molecules have been produced under good manufacturing practice conditions and given systemically to patients with a variety of neoplasms. The promising results to date and the remaining pharmacological hurdles are discussed.

Original languageEnglish (US)
Pages (from-to)326-334
Number of pages9
JournalClinical Cancer Research
Issue number2
StatePublished - Feb 1 2000


ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Frankel, A. E., Kreitman, R. J., & Sausville, E. A. (2000). Targeted toxins. Clinical Cancer Research, 6(2), 326-334.